


**FIGURE 2: AZOLE NUCLEOSIDE ISOMERS**



Ribavirin	
Cells	$\text{CC}_{50}$ , $\mu\text{M}$
MDBK	: 5
HepG2	: 90
PBM	: >100
Vero	: >100
CEM	: 75

FIGURE 3: CYTOPATHIC EFFECT (CPE) ASSAY




FIGURE 4: TOXICITY OF C2-MAD IN BALB/C MICE




FIGURE 5: STANDARD CURVE FOR BYDV




FIGURE 6: GROWTH DYNAMICS OF BVDV IN MDBK CELLS





FIGURE 7: BVDV IN MDBK SUPERNATANT OVER A 4-DAY INCUBATION PERIOD



**FIGURE 8:** ANTI-BVDV COMPOUND (40  $\mu$ M) IN MDBK CELLS

**NO:** No Treatment;  
**RIB:** Ribavirin;  
**A:**  $\beta$ -CH<sub>2</sub>-TAD;  
**B:** Benzamide Riboside;  
**C:** C2-MAD;  
**D:** C2-MPAcid;  
**E:** C2-MPAlddehyde;  
**F:** C4-MPAcid;  
**G:** C4-MPAlddehyde;  
**H:** C6-MAD;  
**I:** F-ara-CH<sub>2</sub>-BAD;  
**J:** F-ara-TAD;  
**K:** MPA;  
**L:** Benzyl-C2-MPA-O-Mesyl;  
**M:** Tiazofurin;  
**N:** Mizoribine




FIGURE 9: DOSE RESPONSE OF C2-MAD RELATIVE TO RIBAVIRIN (RIB) AND TIAZOFURIN




FIGURE 10: ANTIVIRAL EFFECT AFTER ADDITION OF EXOGENOUS GUANOSINE